Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Philogen

- PMLiVE

Servier signs cancer collaboration with Cellectis

Will target leukaemia and five solid tumours

- PMLiVE

FDA clears J&J’s Imbruvica for leukaemia

Adds to cancer drug's lymphoma indication

- PMLiVE

Boehringer switches diabetes candidate in Zealand collaboration

Will swap ZP2929 for another GLP-1 receptor agonist

- PMLiVE

Boehringer names new UK MD

Zinta Krumins has been with company for 25 years

- PMLiVE

FDA to assess safety of Boehringer’s Pradaxa

US regulator plans study to compare the anticoagulant with warfarin

- PMLiVE

Survey to gauge impact of doctor-patient talks in diabetes

Lilly and Boehringer sponsor worldwide study

- PMLiVE

Boehringer’s faldaprevir set for rapid review in Europe

More competition in emerging hepatitis C market

- PMLiVE

Ariad’s cancer drug to remain on EU market

But EMA restricts use of Iclusig due to blood clot risk

- PMLiVE

Boehringer to help promote genetic biomarker testing

Will support Bonnie J Addario Lung Cancer Foundation

- PMLiVE

EMA to review safety of Ariad’s Iclusig

Product information will be updated to warn of blood clot risk

Interview: Allan Hillgrove, Boehringer

Boehringer’s head of sales and marketing on access, partnerships and China on an important year for the German pharma company

- PMLiVE

FDA suspends sale of Ariad’s cancer drug

Iclusig linked to increased risk of blood clots

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links